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Summary — Non-animal science in toxicology and health research has been progressing for decades, but
only now is it being seen widely as advanced science. The emergence of novel human biology-based tools
and models, combined with legislative and regulatory change, a 21st century concept for toxicology,
continuing failures in the drug pipeline, and systematic critiques of animal models, have created a pivotal
moment of change. The leading edge is starting to become the norm. Humans and other animals are likely
to benefit as a result.
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Introduction
Possibly the only advantage to broaching your
sixth decade is the dubious pleasure of taking the
long view of what has gone before (and why).
Probably the major drawback is that you risk
becoming one of those boring seniors who only talk
about the past. But, since those who ignore history
are condemned to repeat it, this piece aims to look
at the replacement of animal experiments in a
timeline running from the past to the future, and
from a distinctively personal viewpoint.
Starting with the present, stretched slightly to
include 2007, I suggest the turning point for nonanimal science has to have been the publication
of the US National Research Council’s (NRC)
ground-breaking report on 21st century toxicology (1).

A new Nobel Prize?
I’m embarrassed to say that, despite the wisdom of
years, I didn’t fully realise the significance of the
NRC report when it was first published; but subsequent developments have been so positive that I
would want to nominate the authors of the report
for the Nobel Prize for Replacing Animal
Experiments. And that would be ironic, because
the whole drive, reason and focus of that extraordinary report was to do better, 21st century, science — and not primarily to replace animal tests.
The authors understood that advanced science had
to mean less reliance on animal tests, and they
found a way to convince scientific leaders around
the world of this truth.

aThe

The authors’ “vision” was to see that the only way
toxicology could respond to modern demands was to
throw out the conventional approach entirely, and
their “strategy” was to develop a crazy new paradigm for safety testing. Their proposal — to move
away from the measurement of apical endpoints in
animals (the black-box approach for more than 60
years) toward an understanding of human pathways of toxicity that disrupt healthy function in
cells, organs and individuals — was an ambitious
masterstroke.
Quantitative structure–activity relationships
(QSARs) would be followed by high-throughput in
vitro biological screening assays to detect toxic perturbations in gene, protein and other cellular pathways, by using molecular and cellular tools. More
in-depth information would derive mainly from
high-content cellular assays, or three-dimensional
tissue constructs, using human cells wherever possible. Animal studies would be resorted to only
occasionally and from necessity. The data generated would be integrated and extrapolated for hazard identification and risk assessment, by using
systems biology and related tools.
This conceptual transformation in toxicology
only became possible because of pragmatic developments in science over the last decade or two,
such as the Human Genome Project, the whole
suite of ‘omics’ techniques (2), the potential of
adult human induced pluripotent stem cells (3),
tissue engineering (4) and microfluidics (5), multiplexed high-content analytical tools (6), and massive advances in bioinformatics (7).
It was the genius of the NRC authors to recognise and seize this scientific turning point, and to
present their plan as a realistic concept that is
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achieving huge buy-in from essential stakeholders.
The first impact of their vision and strategy was
subsequently intensified by workshops, special
issues of journals, high-quality media coverage,
and new government, industry and NGO consortia
and initiatives, set up to progress the work globally. You will recognise the diverse cast of
characters, including the US multi-agency Tox21
consortium (8), the Environmental Protection
Agency’s ToxCast programme (9), the European
Union’s AXLR8 coordination action (10), the
Transatlantic Think Tank of Toxicology (11), the
Human Toxicology Project Consortium (12), and
the Adverse Outcome Pathway programme (13) of
the Organisation for Economic Co-operation and
Development (OECD), among others.
One aspect of my recent work as Senior Scientific Advisor to Humane Society International (HSI)
has been to help promote the 21st century toxicology transition in the European Union (EU). In
2012, HSI organised a European Parliament workshop hosted by Mario Pirillo MEP, on advancing
safety science and health research under Horizon
2020 with innovative, non-animal tools. My report
of the same title was launched at the workshop
(14), and speakers from different member states
presented their research in support of that theme.
Representing HSI, I suggested that the medical
research community needs to consider its own paradigm change, moving the strategic focus of disease modelling and drug discovery away from
animal experiments and toward understanding
human disease pathways by using advanced
research techniques. That the 2013 EU draft
agreement on a specific programme implementing
Horizon 2020 has recognised the value of essential
technologies, such as bioinformatics and systems
biology, the ‘omics’, molecular tools and cell-based
platforms, is a good first step.

Today Toxicology, Tomorrow Health
Research
Most of my career as an ‘animal rights scientist’ has
straddled the medical research/toxicology divide. I
became head of science at the Dr Hadwen Trust for
Humane Research in 1979, when cell culture was
only two-dimensional and relied solely on rather
abnormal immortalised cell lines, and computer
modelling was little more than a gleam in Dorothy
Hegarty’s eye (the founder of FRAME recognised the
potential of computational modelling long before
most of us). We developed the prototype of the
Bovine Corneal Opacity and Permeability (BCOP)
assay for eye irritation during the 1980s (15–17). In
2009, after quarter of a century, it was accepted by
the OECD as a partial replacement for the Draize
rabbit eye test for identifying corrosives and severe
eye irritants, and in 2013, it was one of the first in
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vitro tests to be approved for characterising
chemicals as non-irritant (18).
The Dr Hadwen Trust was the first funder to
recognise the potential for replacing animals of
new functional neuroimaging and related techniques, with its support for magnetoencephalography in 1992 (19), and in 1998 for transcranial
magnetic stimulation as a ‘virtual’ lesioning technique (20). Those technologies have partly replaced
electrophysiological and lesioning experiments on
non-human primates (21) with non-invasive studies of the human brain (22, 23).
One of my early forays into non-animal toxicology was to research and write an in-depth report
for Constantine and Weir (whose mail order business, Cosmetics to Go, was Lush’s predecessor),
called Alternatives to Animal Tests in Cosmetic
Toxicology. It was produced in 1990 as a technical
submission to the European Commission regarding the Cosmetics Directive (76/768/EEC). For
the time, it was a pioneering and comprehensive
review of potential replacement methods, including
computer modelling, Neutral Red and MTT cytotoxicity assays, QSARs, human skin samples in vitro,
volunteer studies, and much more. The RSPCA
Research Animals Department hailed it as “a great
work... enormously useful to the Department”. My
long relationship with the ever-changing Cosmetics Directive goes back to its 1980 incarnation.
I was introduced to it by the then managing director of Yardley, who recognised that it would
increase animal testing, which it did. Latterly, of
course, it has reversed that direction, definitively.
In terms of implementing animal replacement
techniques and policy development, although the
pace has sometimes seemed glacial, toxicology has
always been ahead of medical research. My plenary lecture at the Third World Congress on
Alternatives in 1999 emphasised that while nonanimal safety tests were progressing, disease
research and drug discovery faced different challenges: research questions were more open-ended
and the research enterprise not so constrained by
regulatory and legislative changes. For example,
whilst the Cosmetics Directive was constantly
amended as public concern about animal testing
increased, medical researchers were insulated
from this type of influence and were more focused
by pressures such as conservative peer-review and
established funding policies (24). It’s a theme I’ve
pursued for a long time in an effort to shift the
framework of health research away from its animal model focus (25).

A ‘Macro-change’ Moment
We always considered non-animal techniques to be
ethically advanced, but it’s only in this century
that the required scientific tools have emerged to
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really justify the claim, across the board, that
human biology-based approaches are genuine
advances. ‘Humane science’ has become ‘advanced
science’. In health research, systematic analyses of
the performance of animal models will likely be
important in driving progress (26). As long as
researchers are allowed to remain in denial about
the validity of their animal models, they will not
consider significant change. I suggest that systematic reviews and meta-analyses of the predictivity
of animal studies will continue to show that species
barriers can never be entirely designed away, and
that the emperor has no clothes (or at least, little
more than flimsy underwear).
You probably have to be an optimist to sustain a
three-decade career in animal rights science with
your sanity intact. There is no doubt there are
many sizeable technical, conceptual and policy barriers to overcome. It has never been enough to simply fund non-animal replacement research and
testing methods: constant advocacy and promotion
are essential. I’ve always enjoyed gauging the precise optimum between a confrontational approach,
which repels many people, and a passive politeness, which persuades no-one of the need for
change. As a member of the government’s Animal
Procedures Committee (1998–2006), I honed that
talent to a knife-edge, and saw quite dramatic
progress in the nature of the committee’s working
processes over those years.
Looking in the rear-view mirror, so to speak, the
times when progress seemed out of reach were
probably times of multiple micro-changes, each too
small to notice. But at a certain threshold, macrochange erupts and the leading edge starts to
become the norm. It’s difficult to predict those
moments, but we are living through one now: a
coming-together of advanced scientific and technological developments gaining widespread recognition; legislative and regulatory change providing
the setting; a new concept for toxicology being
articulated; continuing disappointments in the
drug pipeline worrying the pharma industry (27);
and ongoing critiques of animal models appearing
in the literature (28–32).
Together these have created a synergy with irresistible momentum. For a long time, many of us
have shared a vision of doing excellent science
without harming animals, and at this pivotal
moment it seems it can become a reality. If so, all
of us — humans and other animals together — will
benefit.
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